Viewing Study NCT01238692

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:37 PM
Ignite Modification Date: 2026-01-24 @ 6:31 AM
Study NCT ID: NCT01238692
Status: COMPLETED
Last Update Posted: 2023-03-24
First Post: 2010-11-10
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)
Sponsor: Sarit Assouline
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Diffuse Large B Cell Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Diffuse large B cell lymphoma View
None DLBCL View
None Relapsed B-cell lymphoma View
None Refractory B-cell lymphoma View
None B-cell Lymphoma View
None Panobinostat View
None LBH589 View
None Rituximab View
None Histone Deacetylase Inhibitors View